Work

Understanding and Predicting Variability in Response to Treatment in Psychotic Disorders: In Vivo Findings

Year: 2019

Type: article

Abstract: O.D.H. has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Astra-Zeneca, Autifony, BMS, Eli Lilly, Heptares, Janssen, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, Rand and Roche. Neither O.D.H. nor his family have been employed by or have holdings/a financial stake in any biomedical company. S.J. reports no conflict of interest.

Source: Clinical Pharmacology & Therapeutics

DOI: 10.1002/cpt.1357

Authors: Sameer Jauhar, Oliver D. Howes

Institutions: King's College London, Hammersmith Hospital, MRC London Institute of Medical Sciences, Imperial College London, Medical Research Council

Language: English

Topic: Schizophrenia research and treatment

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green